Proteomics-a blessing or a curse? application of proteomics technology to transplant medicine

Transplantation

Volumn 92, Issue 5, 2011, Pages 499-509

  Kienzl Wagner, Katrin ^a   Pratschke, Johann ^a   Brandacher, Gerald ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Proteomics; Transplantation

Indexed keywords

BIOLOGICAL MARKER;

CLINICAL RESEARCH; DRUG TARGETING; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TRANSPLANTATION;

ANIMALS; BIOLOGICAL MARKERS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; KIDNEY TRANSPLANTATION; MASS SPECTROMETRY; PROTEIN ARRAY ANALYSIS; PROTEOMICS; TRANSPLANTATION IMMUNOLOGY;

EID: 80052394590     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182265358     Document Type: Review

References (72)

1. Smith MP, Banks RE, Wood SL, et al. Application of proteomic analysis to the study of renal diseases. Nat Rev Nephrol 2009; 5: 701.
2. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science 2006; 312: 212.
3. Tyers M, Mann M. From genomics to proteomics. Nature 2003; 422: 193.
4. Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000; 405: 837.
5. Graves PR, Haystead TA. Molecular biologist's guide to proteomics. Microbiol Mol Biol Rev 2002; 66: 39.
6. McGregor E, Dunn MJ. Proteomics of heart disease. Hum Mol Genet 2003; 12(Spec No 2): R135.
7. Sarwal MM. Chipping into the human genome: Novel insights for transplantation. Immunol Rev 2006; 210: 138.
8. Findeisen P, Neumaier M. Mass spectrometry-based clinical proteomics profiling: Current status and future directions. Expert Rev Proteomics 2009; 6: 457.
9. Patterson SD, Aebersold RH. Proteomics: The first decade and beyond. Nat Genet 2003; 33(suppl): 311.
10. Hanash S. Disease proteomics. Nature 2003; 422: 226.
11. Schaub S, Wilkins JA, Rush D, et al. Developing a tool for noninvasive monitoring of renal allografts. Expert Rev Proteomics 2006; 3: 497.
12. Mannon RB, Kirk AD. Beyond histology: Novel tools to diagnose allograft dysfunction. Clin J Am Soc Nephrol 2006; 1: 358.
13. Nickerson P. Post-transplant monitoring of renal allografts: Are we there yet? Curr Opin Immunol 2009; 21: 563.
14. Veenstra TD, Prieto DA, Conrads TP. Proteomic patterns for early cancer detection. Drug Discov Today 2004; 9: 889.
15. Matt P, Fu Z, Fu Q, et al. Biomarker discovery: Proteome fractionation and separation in biological samples. Physiol Genomics 2008; 33: 12.
16. Tonge R, Shaw J, Middleton B, et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001; 1: 377.
17. Alban A, David SO, Bjorkesten L, et al. A novel experimental design for comparative two-dimensional gel analysis: Two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003; 3: 36.
18. Karp NA, Kreil DP, Lilley KS. Determining a significant change in protein expression with DeCyder during a pair-wise comparison using twodimensional difference gel electrophoresis. Proteomics 2004; 4: 1421.
19. Weissinger EM, Hertenstein B, Mischak H, et al. Online coupling of capillary electrophoresis with mass spectrometry for the identification of biomarkers for clinical diagnosis. Expert Rev Proteomics 2005; 2: 639.
20. Ahmed FE. Utility of mass spectrometry for proteome analysis: Part I. Conceptual and experimental approaches. Expert Rev Proteomics 2008; 5: 841.
21. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003; 422: 198.
22. Ahmed FE. Utility of mass spectrometry for proteome analysis: Part II. Ion-activation methods, statistics, bioinformatics and annotation. Expert Rev Proteomics 2009; 6: 171.
23. Sleno L, Volmer DA. Ion activation methods for tandem mass spectrometry. J Mass Spectrom 2004; 39: 1091.
24. Traum AZ, Schachter AD. Transplantation proteomics. Pediatr Transplant 2005; 9: 700.
25. Sigdel TK, Klassen RB, Sarwal MM. Interpreting the proteome and peptidome in transplantation. Adv Clin Chem 2009; 47: 139.
26. Stoevesandt O, Taussig MJ, He M. Protein microarrays: High-throughput tools for proteomics. Expert Rev Proteomics 2009; 6: 145.
27. Clarke W, Silverman BC, Zhang Z, et al. Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 2003; 237: 660.
28. Schaub S, Rush D, Wilkins J, et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004; 15: 219.
29. Schaub S, Wilkins JA, Antonovici M, et al. Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am J Transplant 2005; 5(4 pt 1): 729.
30. Schaub S, Mayr M, Honger G, et al. Detection of subclinical tubular injury after renal transplantation: Comparison of urine protein analysis with allograft histopathology. Transplantation 2007; 84: 104.
31. O'Riordan E, Orlova TN, Mei JJ, et al. Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol 2004; 15: 3240.
32. O'Riordan E, Orlova TN, Podust VN, et al. Characterization of urinary peptide biomarkers of acute rejection in renal allografts. Am J Transplant 2007; 7: 930.
33. Wittke S, Haubitz M, Walden M, et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant 2005; 5: 2479.
34. Ling XB, Sigdel TK, Lau K, et al. Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection.JAmSoc Nephrol 2010; 21: 646.
35. Sigdel TK, Kaushal A, Gritsenko M, et al. Shotgun proteomics identifies proteins specific for acute renal transplant rejection. Proteomics Clin Appl 2010; 4: 32.
36. Sigdel TK, Ling XB, Lau KH, et al. Urinary peptidomic analysis identifies potential biomarkers for acute rejection of renal transplantation. Clin Proteom 2009; 5: 103.
37. Freue GV, Sasaki M, Meredith A, et al. Proteomic signatures in plasma during early acute renal allograft rejection. Mol Cell Proteomics 2010; 9: 1954.
38. Sui W, Huang L, Dai Y, et al. Proteomic profiling of renal allograft rejection in serum using magnetic bead-based sample fractionation and MALDI-TOF MS. Clin Exp Med 2010; 10: 259.
39. Wu D, Zhu D, Xu M, et al. Analysis of transcriptional factors and regulation networks in patients with acute renal allograft rejection. J Proteome Res 2011; 10: 175.
40. Qian WJ, Jacobs JM, Liu T, et al. Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics 2006; 5: 1727.
41. Quintana LF, Campistol JM, Alcolea MP, et al. Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol Cell Proteomics 2009; 8: 1658.
42. Quintana LF, Sole-Gonzalez A, Kalko SG, et al. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol 2009; 20: 428.
43. O'Riordan E, Orlova TN, Mendelev N, et al. Urinary proteomic analysis of chronic allograft nephropathy. Proteomics Clin Appl 2008; 2: 1025.
44. Bañón-Maneus E, Diekmann F, Carrascal M, et al. Two-dimensional differencegel electrophoresisurinaryproteomicprofile inthesearchofnonimmune chronic allograft dysfunction biomarkers. Transplantation 2010; 89: 548.
45. Nakorchevsky A, Hewel JA, Kurian SM, et al. Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies. J Am Soc Nephrol 2010; 21: 362.
46. Nickerson P, Heeger PS. Proteomic portrayal of transplant pathologies. J Am Soc Nephrol 2009; 20: 236.
47. Kurian SM, Heilman R, Mondala TS, et al. Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS One 2009; 4: e6212.
48. Deckers JW, Hare JM, Baughman KL. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: A seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. J Am Coll Cardiol 1992; 19: 43.
49. Baraldi-Junkins C, Levin HR, Kasper EK, et al. Complications of endomyocardial biopsy in heart transplant patients. J Heart Lung Transplant 1993; 12(1 pt 1): 63.
50. Navia JL, Atik FA, Vega PR, et al. Tricuspid valve repair for biopsyinduced regurgitation in a heart transplant recipient. J Heart Valve Dis 2005; 14: 264.
51. Borozdenkova S, Westbrook JA, Patel V, et al. Use of proteomics to discover novel markers of cardiac allograft rejection. J Proteome Res 2004; 3: 282.
52. Kienzl K, Sarg B, Golderer G, et al. Proteomic profiling of acute cardiac allograft rejection. Transplantation 2009; 88: 553.
53. Rose ML, Dunn MJ. Biomarkers of rejection: Are we any closer to the Philosopher's Stone? Transplantation 2009; 88: 453.
54. Meirovich YF, Veinot JP, de Bold ML, et al. Relationship between natriuretic peptides and inflammation: Proteomic evidence obtained during acute cellular cardiac allograft rejection in humans. J Heart Lung Transplant 2008; 27: 31.
55. De Souza AI, Wait R, Mitchell AG, et al. Heat shock protein 27 is associated with freedom from graft vasculopathy after human cardiac transplantation. Circ Res 2005; 97: 192.
56. Trott D, McManus CA, Martin JL, et al. Effect of phosphorylated hsp27 on proliferation of human endothelial and smooth muscle cells. Proteomics 2009; 9: 3383.
57. Jahnukainen T, Malehorn D, Sun M, et al. Proteomic analysis of urine in kidney transplant patients with BK virus nephropathy. J Am Soc Nephrol 2006; 17: 3248.
58. Nelsestuen GL, Martinez MB, Hertz MI, et al. Proteomic identification of human neutrophil alpha-defensins in chronic lung allograft rejection. Proteomics 2005; 5: 1705.
59. Funding M, Vorum H, Honore B, et al. Proteomic analysis of aqueous humour from patients with acute corneal rejection. Acta Ophthalmol Scand 2005; 83: 31.
60. Kaiser T, Kamal H, Rank A, et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 340.
61. Weissinger EM, Schiffer E, Hertenstein B, et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007; 109: 5511.
62. Pan TL, Wang PW, Huang CC, et al. Expression, by functional proteomics, of spontaneous tolerance in rat orthotopic liver transplantation. Immunology 2004; 113: 57.
63. Hsu LW, Goto S, Nakano T, et al. Immunosuppressive activity of serum taken from a liver transplant recipient after withdrawal of immunosuppressants. Transpl Immunol 2007; 17: 137.
64. Koomen JM, Wilson CR, Guthrie P, et al. Proteome analysis of isolated perfused organ effluent as a novel model for protein biomarker discovery. J Proteome Res 2006; 5: 177.
65. Cheng J, Zhou L, Jiang JW, et al. Proteomic analysis of differentially expressed proteins in rat liver allografts developed acute rejection. Eur Surg Res 2010; 44: 43.
66. Svetlov SI, Xiang Y, OliMW,et al. Identification and preliminary validation of novel biomarkers of acute hepatic ischaemia/reperfusion injury using dualplatform proteomic/degradomic approaches. Biomarkers 2006; 11: 355.
67. Voshol H, Brendlen N, Muller D, et al. Evaluation of biomarker discovery approaches to detect protein biomarkers of acute renal allograft rejection. J Proteome Res 2005; 4: 1192.
68. Dai Y, Lv T, Wang K, et al. Detection of acute renal allograft rejection by analysis of renal tissue proteomics in rat models of renal transplantation. Saudi J Kidney Dis Transpl 2008; 19: 952.
69. El Essawy B, Otu HH, Choy B, et al. Proteomic analysis of the allograft response. Transplantation 2006; 82: 267.
70. Yamayoshi Y, Watanabe T, Tanabe M, et al. Novel application of ProteinChip technology exploring acute rejection markers of rat small bowel transplantation. Transplantation 2006; 82: 320.
71. Byrne GW, Stalboerger PG, Davila E, et al. Proteomic identification of non-Gal antibody targets after pig-to-primate cardiac xenotransplantation. Xenotransplantation 2008; 15: 268.
72. Truffa-Bachi P, Lefkovits I I, Rudolf Frey J. Proteomic analysis of T cell activation in the presence of cyclosporin A: Immunosuppressor and activator removal induces de novo protein synthesis. Mol Immunol 2000; 37: 261. (Pubitemid 30603974)